A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. These returns cover a period from January 1, 1988 through July 6, 2020. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.33% per year. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -9.23 and a beta of 1.75.
CRISPR Therapeutics commands a market valuation of $3.8 billion, more than four times the $900.2 million market cap of Intellia. Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%Summit Hotel Properties (NYSE:INN) Shares Up 0.4%Several hedge funds have recently modified their holdings of NTLA. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.64 and a quick ratio of 7.64. Intellia Therapeutics upgraded to outperform from … Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.As an investor, you want to buy stocks with the highest probability of success.
Intellia Therapeutics, Inc. est une société d'édition de génome.
The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. Financially, both companies have plenty of cash to operate and are reporting losses as they continue to develop their drug candidates. Intellia Therapeutics stock price target cut to $16 from $21 at Wedbush Feb. 14, 2020 at 7:16 a.m. This is done because, generally speaking, if an analyst reevaluates their earnings estimate right before an earnings release, it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago.As an investor, you want to buy stocks with the highest probability of success. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
(RTTNews) - Shares of Intellia Therapeutics Inc. (NTLA) were down 3.68% and closed Friday's trading session at $13.62. In the pre-market session today, the stock … Hedge funds and other institutional investors own 90.46% of the company’s stock.Sprott Physical Platinum and Palladium (NYSEARCA:SPPP) Shares Up 2%General Moly (NYSEAMERICAN:GMO) Trading Up 20.7% Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Stock analysis for Intellia Therapeutics Inc (NTLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. How good is it? Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) were down 3.5% during mid-day trading on Wednesday .
Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Friday, May 8th. The stock had previously closed at $20.96.